The inherent challenges within the domain of tissue engineering often stem from the necessity of blood circulation within these artificial constructs. Blood flow is essential for providing nutrients and oxygen to cells, enabling their survival and functionality. However, consistently maintaining a functional vascular system within three-dimensional structures poses significant hurdles. Without an adequate vasculature, engineered tissues can quickly succumb to necrosis, rendering them ineffective for research or therapeutic applications.

In the recent publication featured in the journal Biomedical Materials, Assistant Professors Ying Wang and Yingge Zhou, along with a dedicated team of doctoral students and postdoctoral researchers, have showcased innovative approaches utilizing advanced nanomanufacturing techniques. Their research primarily focuses on the creation of a sophisticated vascular system that could be integrated seamlessly into engineered tissues. This advancement not only addresses existing limitations but also paves the way for future explorations into organ-specific tissue scaffolds.

One of the most compelling aspects of their research lies in the multi-tiered approach to vascular design. Wang articulated that their engineered vascular construct mimics the hierarchical architecture seen in natural vascular systems. Notably, they synthesized larger blood vessels analogous to our aorta and main veins, while simultaneously employing spontaneous self-assembly for the creation of smaller arteries. This sophisticated strategy exemplifies a pivotal leap in the design of vascular networks, as it allows flexibility in creating varied blood vessel sizes according to functional requirements.

Furthermore, the researchers have harnessed two commonly used inert compounds in biomedical devices, polyethylene oxide (PEO) and polystyrene (PS), to fabricate microtubes. These microtubes serve as an essential component in their engineered tissues, promoting enhanced nutrient distribution and oxygen flow. The technique they employed, known as electrospinning, enabled the production of ultra-fine fibers at an unprecedented scale. This method is especially critical, as 3D printing techniques often struggle to achieve the resolution required for such minute structures.

Zhou elaborated on the specifics of their fabrication process, detailing how they created microtubes that measure between 1 to 10 microns. To put this into perspective, a single micron is one-millionth of a meter. The typical human hair is approximately 70 to 100 microns thick. Thus, managing the precision at this microscopic scale is a considerable technical achievement, necessitating sophisticated methods like electrospinning to create solid microtubes, which are then hollowed out by dissolving their cores.

The integration of these finely crafted fibrous tubes into a composite hydrogel forms a vital part of the medium used for tissue growth. The collaborative team adeptly utilized fluorescent microbeads to track blood flow within the engineered tissue, revealing that the incorporation of these microtubes significantly improved blood distribution. As a result, cells within the constructed tissues received the necessary nutrients and oxygen, ultimately expanding their viability for further research and applications.

Binghamton University’s research team anticipates novel avenues of exploration as they look to further understand how alterations in the dimensions and configurations of these microtubes could influence vascular outcomes. Additionally, they aim to develop specialized microvasculature that mimics the characteristics of specific organs, such as the complex blood-brain barrier. This pursuit is particularly crucial, as comprehending the intricacies of the blood-brain barrier is key to advancing treatments for various neurological conditions, including tumors and neurodegenerative diseases.

The overarching goal of this groundbreaking research is to enhance the physiological relevance of engineered tissues, making them more representative of actual human biology. Wang underscored the potential of their work, expressing a vision where perfected vascular technology could lead to the assembly of entire organ systems mimicking living, functional human tissues. Achieving this milestone would revolutionize tissue engineering, allowing for personalized medicine approaches and advanced studies that significantly improve health outcomes.

With the intense focus on organ-specific applications, the future of this research appears bright and filled with potential. The next steps will likely involve rigorous examinations of how microstructural adjustments impact tissue performance and how these findings can be applied to clinical settings. The implications of this research extend far beyond the laboratory, heralding a new era of personalized healthcare where engineered tissues could be used not just for drug testing but also for repairing damaged organs and tissues in real patients.

In conclusion, the collaborative efforts at Binghamton University highlight a major advancement in the quest for effective engineered tissues, offering hope for myriad applications in regenerative medicine and drug development. With the right resources and continued research, the integration of sophisticated vascular networks within artificial tissues could indeed transform the way we approach health and disease, making significant strides towards a healthier future.

Subject of Research: Human tissue samples
Article Title: Engineering polystyrene microtube-embedded composite hydrogels for tunable vascular morphogenesis
News Publication Date: 18-Jul-2025
Web References: Link to Journal
References: Biomedical Materials journal article
Image Credits: Jonathan Cohen/Binghamton University

Keywords

Biomedical engineering, tissue engineering, vascular systems, nanomanufacturing, organ-specific scaffolds.

The heart plays a critical role in human physiology, and any malfunction within its structure can lead to dire health consequences. Traditional replacements for damaged pulmonary valves often involve mechanical or donor valves, which come with a range of complications including rejection, limited durability, and the necessity for long-term anticoagulation therapy. By tapping into the body’s inherent abilities to heal and regenerate, the researchers aimed to create an alternative that minimizes these risks and promotes natural integration.

The study’s primary focus was on harnessing the patient’s own cells to fabricate the pulmonary valves, promoting biocompatibility and reducing the chances of immune rejection. The researchers developed a sophisticated method for harvesting stem cells from patients, which were then differentiated into suitable cardiac tissue. By doing this, Sato and colleagues not only utilized the body’s own healing mechanisms but also ensured that the engineered valves would be functionally and histologically appropriate for heart function.

The researchers employed a novel transcatheter approach, allowing the delivery of these pulmonary valves via a minimally invasive procedure. This technique significantly reduces recovery times and postoperative complications associated with traditional open-heart surgery. Moreover, the transcatheter method allows for real-time monitoring and adjustments during implantation, providing an unprecedented level of precision in cardiac interventions.

The team’s design leveraged advanced three-dimensional printing technology, which enabled the creation of scaffolds mimicking the complex architecture of natural pulmonary valves. This sophistication is crucial, as the biomechanical properties of valves can determine their longevity and compatibility with surrounding tissue. The use of biodegradable materials in the scaffolding process allowed for gradual integration with the patient’s natural tissue, ensuring that the transcatheter valves function effectively in the dynamic environment of the heart.

One of the core innovations of this study lies in the incorporation of in-body tissue architecture when fabricating these valves. By mimicking the natural extracellular matrix, this technique enables the engineered valves to encourage cell growth and proliferation. Such an approach tempts the body to treat the new valve as part of its own structure, significantly enhancing the longevity and functionality of the implant.

Moreover, the researchers presented substantial preclinical data demonstrating that the new valves successfully exhibited excellent hemodynamic properties. They addressed concerns regarding the potential for calcification, a common complication observed with synthetic implants. The study revealed that autologous tissue-engineered valves exhibited significantly reduced calcification compared to conventional alternatives, pointing to their potential for long-term use.

The researchers emphasized the importance of conducting extensive clinical trials to validate their findings and understand the long-term implications of using these valves in human patients. Initial studies on animal models showcased promising results, bolstering their confidence in moving towards human applications. However, the transition from laboratory success to clinical efficacy will require careful examination and experimentation.

Furthermore, the impact of this research extends beyond mere implantation. The use of patients’ own cells minimizes ethical concerns surrounding tissue sourcing, while the development of in-body engineered solutions could potentially vastly improve patient outcomes and revolutionize how we approach heart diseases. Such advancements offer hope for tailored therapies based on individual patient profiles, fostering a new era of personalized medicine.

The status of pulmonary valve replacements and the widespread need for improved methodologies in treating heart valve diseases highlights the timely importance of this research. Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, making innovative solutions such as those proposed by Sato and his colleagues essential. Their work represents a significant step forward in the quest to provide better options for patients suffering from heart valve dysfunctions.

Industry experts have already begun to take notice of these promising developments, speculating on potential future implications for broader applications in the field of regenerative medicine. The potential for these engineered solutions to be adapted for other types of valves or even for general applications in tissue engineering might transform not just cardiology but various domains within medical practice.

The implications of this research also pave the way for discussions about healthcare policies, insurance coverage for advanced treatments, and the allocation of resources in medical research. If proven successful, the widespread adoption of such transcatheter solutions could lead to decreased healthcare costs over time due to fewer procedures and complications, ultimately benefiting patients both financially and health-wise.

As the medical community reflects on these advances, it’s vital to remain engaged in dialogue regarding the ethical considerations surrounding the use of bioprinting and tissue engineering technologies. While the benefits appear vast, the ensure balance between innovation, patient safety, and ethical practices in research and treatment must remain at the forefront of scientific endeavors.

In conclusion, the study spearheaded by Sato, Inoue, and Terazawa provides a glimmer of hope in the ongoing battle against heart disease. The innovative approach of using autologous tissue-engineered pulmonary valves represents a leap toward more effective, biocompatible, and patient-forward solutions. As research continues to advance and clinical trials unfold, there’s a palpable sense of anticipation regarding the potential for these innovations to reshape the landscape of cardiac treatment in the years to come.

Subject of Research: Development of transcatheter implantable autologous tissue-engineered pulmonary valves.

Article Title: Development of transcatheter implantable autologous tissue-engineered pulmonary valves using in-body tissue architecture.

Article References:

Sato, Y., Inoue, Y., Terazawa, T. et al. Development of transcatheter implantable autologous tissue-engineered pulmonary valves using in-body tissue architecture.
J Artif Organs 28, 393–401 (2025). https://doi.org/10.1007/s10047-025-01507-w

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10047-025-01507-w

Keywords: Tissue engineering, pulmonary valves, cardiac treatment, regenerative medicine, biocompatibility, transcatheter approach, personalized medicine, heart disease, autologous solutions, ethical considerations in medicine.

Mikos’s pioneering work bridges fundamental biomaterials science with translational applications in medicine. His research portfolio spans sophisticated strategies for developing biocompatible scaffolds that mimic the extracellular matrix, enabling the regeneration of complex tissues. He has extensively explored synthetic and natural polymer systems tailored to degrade at controlled rates, releasing therapeutic agents in a spatiotemporally regulated manner. These innovations have had far-reaching implications in orthopedic, dental, cardiovascular, neurologic, and ophthalmologic medicine, advancing patient-specific regenerative solutions.

Central to Mikos’s research is the design of multifunctional biomaterials capable of interfacing with biological systems to promote healing and regeneration. His work delves into the intricate signaling pathways involved in tissue repair, leveraging biomaterial chemistry to orchestrate cellular responses. A notable focus is on gene-activated matrices that facilitate localized gene therapy, invigorating endogenous repair mechanisms. This nexus of biomaterials and gene therapy presents a frontier for precision medicine, combining material science with molecular biology.

The engineering of three-dimensional tissue constructs remains a cornerstone of Mikos’s contributions. His laboratory champions the use of porous scaffolds that support cell attachment, proliferation, and differentiation while enabling nutrient diffusion. These structures serve as models for studying disease progression and therapeutic interventions. By integrating microfabrication techniques and bioreactors, Mikos’s team replicates physiological environments to enhance tissue maturation ex vivo, thereby advancing organ repair and replacement paradigms.

Regulated drug delivery systems developed under Mikos’s guidance have reshaped treatment approaches for chronic diseases. These biomaterials provide sustained release profiles, reducing systemic toxicity while maximizing therapeutic efficacy. Customizable delivery vehicles, from hydrogels to nanoparticles, have been engineered to respond to environmental stimuli such as pH and enzymatic activity. Such responsiveness allows for on-demand drug release, optimizing timing and dosage to patient needs.

Mikos’s interdisciplinary collaborations stretch across biomedical engineering, material science, and clinical medicine, underscoring his commitment to translational research. His work not only elucidates foundational principles but also accelerates the path from bench to bedside. The impact of his biomaterials is evident in clinical trials targeting bone regeneration and cartilage repair, including strategies that combat inflammation and infection at injury sites.

Beyond his research achievements, Mikos plays a vital role in shaping the scientific community. As founding editor and editor-in-chief of the Tissue Engineering journals, he has cultivated a platform accelerating discoveries and cross-disciplinary dialogue. Mentorship is a hallmark of his career, fostering a generation of researchers who continue to innovate in regenerative medicine and bioengineering worldwide.

His election to the European Academy of Sciences affirms his status as a global leader whose work transcends national boundaries. The academy’s emphasis on interdisciplinary collaboration and societal impact resonates deeply with Mikos’s vision. He anticipates that membership will augment opportunities to exchange knowledge and contribute to international efforts that harness science and technology for human betterment.

At Rice University, Mikos directs multiple research hubs including the Biomaterials Lab, the Center for Excellence in Tissue Engineering, and the J.W. Cox Laboratory for Biomedical Engineering. These centers epitomize a convergence of basic science and engineering with clinical application, fostering environments where innovative biomaterials evolve from concept to clinical reality. His membership in the National Academy of Engineering, the National Academy of Medicine, and other esteemed societies further underscores his profound influence.

With an impressive publication record exceeding 700 scientific articles and over 30 patented technologies, Mikos’s contributions illustrate an extraordinary blend of creativity and rigor. His research continues to push the boundaries of how engineered biomaterials can emulate and augment biological functions. The widespread clinical adoption of his innovations reflects a transformative impact that extends well beyond academic circles.

The formal induction ceremony for Mikos’s inclusion into the European Academy of Sciences will take place on December 17-18, 2025, during the EURASC Annual Symposium at CERN in Geneva. This event not only honors his past achievements but also heralds new opportunities for advancing collaborative research across continents. Mikos expressed his eagerness to engage with this distinguished community to drive forward the frontiers of knowledge.

The recognition of Antonios Mikos’s accomplishments highlights the essential role of biomaterials science in medicine’s future. As challenges such as organ shortages and chronic disease burdens grow, his work illuminates pathways to engineered solutions capable of repairing and regenerating damaged tissues. Mikos’s visionary approach exemplifies the potency of integrating engineering principles with biological insight to revolutionize healthcare.

Through continuous innovation and leadership, Mikos remains at the forefront of efforts to harness the potential of materials science in healing the human body. His election to the European Academy of Sciences cements a legacy marked by transformative advances, global collaboration, and a steadfast commitment to improving lives through science and engineering.

Subject of Research: Biomaterials and Tissue Engineering in Regenerative Medicine and Controlled Drug Delivery

Article Title: Antonios Mikos Elected to European Academy of Sciences for Pioneering Advances in Biomaterials and Regenerative Medicine

News Publication Date: May 19, 2025

Web References: https://news.rice.edu/

Image Credits: Photo by Gustavo Raskosky/Rice University

Keywords: Regenerative medicine, Tissue engineering, Bioengineering, Engineering, Biomaterials

The skin, as the largest organ of the human body, serves as a complex protective barrier against environmental threats such as pathogens, dehydration, and temperature fluctuations. Despite its vital role, the intricate biological mechanisms underpinning skin diseases—including skin cancer, chronic wounds, and autoimmune disorders—remain only partially understood. To bridge this gap, Empa scientists have embarked on an ambitious project in collaboration with clinical partners to engineer a living, multilayered artificial skin model. This model is designed to emulate the intricate architecture and biochemical environment of natural human skin, enabling researchers to simulate disease mechanisms with unprecedented fidelity.

Central to this endeavor is the advancement of hydrogels—polymeric materials capable of retaining large amounts of water—mimicking the extracellular matrix (ECM) that provides structural and biochemical support to cells. The ECM itself is a complex network comprising proteins and glycoproteins that vary between different skin layers, making it essential to replicate these variations accurately to create viable skin constructs. Traditional hydrogels, while useful, present challenges; upon hydration, they frequently swell, altering their shape and impeding the reproduction of skin’s layered morphology. Empa’s latest discovery turns to nature for a solution by harnessing the gelatin extracted from cold-water fish species such as cod, pollock, and haddock.

This particular fish-derived gelatin can be cross-linked swiftly and efficiently into a hydrogel that resists swelling post-fabrication. The materials science team utilized this characteristic to produce a hydrogel matrix that preserves its form during and after 3D bioprinting. The ability to maintain dimensional stability while embedding living skin cells is a major leap forward, facilitating the construction of biomimetic skin that includes the vital dermis, epidermis, and the critical epidermal-dermal junction, often referred to as the basal membrane. Such structural fidelity is crucial for studying cell-cell interactions and pathological changes that occur at these interfaces in various skin conditions.

The employment of 3D printing technology adds another layer of sophistication to this model. This additive manufacturing method facilitates precise spatial arrangement of multiple cell types within the hydrogel, recapitulating the natural heterogeneity of human skin tissue. Three-dimensional bioprinting empowers researchers to place skin cells, extracellular matrix substitutes, and other biomaterials in tailored patterns, closely mirroring the organized complexity of real skin. The technique’s flexibility also enables the integration of multiple polymers and cellular components within a single construct, pushing the envelope of tissue engineering capabilities.

One of the most remarkable aspects of this development is the hydrogel’s compatibility with living cells, which broadens its applications beyond model skin fabrication. By omitting live cells during production, the fish gelatin hydrogel can serve as an advanced wound dressing. Its biological compatibility reduces the likelihood of immune rejection while minimizing risks related to disease transmission that are typically associated with mammalian gelatin derivatives due to evolutionary distances. This positions the material as a safer, more homogeneous alternative to currently available biologically derived dressings.

Moreover, the intrinsic properties of this hydrogel allow it to be customized with precision to meet patient-specific needs. Variables such as thickness, stiffness, and shape can be finely tuned, opening possibilities for highly personalized wound care solutions. Inclusion of therapeutic agents—ranging from antibiotics to growth factors—within the hydrogel matrix is also under consideration, which could transform wound dressings into active treatment systems that accelerate healing and reduce complications.

The inspiration behind leveraging cold-water fish gelatin stems from its evolutionary divergence from mammals, which reduces immunogenic potential. Empa’s interdisciplinary team, operating within the Swiss research initiative SKINTEGRITY.CH, has tapped into this natural resource to yield a biomaterial exhibiting both mechanical resilience and biofunctionality. Their approach aligns with SKINTEGRITY.CH’s mission to elucidate molecular-level skin responses during injury, disease, and healing by providing researchers with more accurate and representative skin models.

Overcoming the technical challenges of producing a non-swelling hydrogel that remains printable using sensitive biological components represents a considerable achievement. Traditional non-swelling hydrogels are often complex to synthesize or incompatible with living cells and 3D printing techniques. Empa researchers circumvent these problems by exploiting natural gelatin’s biocompatibility alongside an innovative cross-linking technique that balances mechanical strength with cellular viability. This symbiosis between material engineering and biological function underscores the potential impact of their work.

Beyond laboratory research, empirical validation and patent protection efforts are underway. The research team has filed a patent application to safeguard their novel hydrogel formulation, aimed at facilitating widespread adoption in both academic and commercial sectors. Future work revolves around completing the development of the living skin model and distributing it to fellow scientists globally, accelerating translational research into skin diseases and therapeutic interventions.

Additionally, the team is intrigued by the peculiar swelling dynamics of their hydrogel, which diverge from typical polymer behavior. Detailed biophysical studies are planned to investigate these phenomena, with expectations that insights gained might inform further optimization not only for skin models but also for other tissue engineering applications requiring stable biomimetic scaffolds.

In sum, Empa’s breakthrough in creating a mechanically robust, non-swelling hydrogel derived from cold-water fish gelatin, optimized for 3D bioprinting, offers transformative possibilities for the future of skin disease research, wound healing, and regenerative medicine. By faithfully replicating the structure and conditions of human skin within a synthetic platform, scientists can explore disease progression, drug responses, and repair mechanisms more effectively and ethically. As this technology matures, it could herald a new era where personalized, bioprinted skin grafts and advanced wound dressings become commonplace tools in clinical settings.

—

Subject of Research: Cells

Article Title: Mechanically robust non-swelling cold water fish gelatin hydrogels for 3D bioprinting

News Publication Date: 2-Jun-2025

Web References:
http://dx.doi.org/10.1016/j.mtbio.2025.101701

Image Credits: Empa

Keywords

3D bioprinting, cold-water fish gelatin, hydrogel, skin model, extracellular matrix, non-swelling hydrogel, tissue engineering, wound healing, biomaterials, SKINTEGRITY.CH, regenerative medicine, biomimetic skin